Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

BRAF Mutation Triggers Series of Cellular Transformations Leading to Colon Cancer

By BiotechDaily International staff writers
Posted on 23 Jul 2013
Cancer researchers have found that the activity of the protein encoded by the mutant BRAFV600E gene triggers a series of transformations (hyperplasia to adenoma to carcinoma) that convert normal cells in the colon into a precancerous and ultimately fully cancerous state.

The BRAF (v-Raf murine sarcoma viral oncogene homolog B1) gene encodes the protein serine/threonine-protein kinase B-Raf. About half of melanomas express the BRAFV600E mutation (at amino acid position number 600 on the B-Raf protein, the normal valine is replaced by glutamic acid). Inhibitors of B-Raf such as vemurafenib have been approved for the treatment of metastatic melanoma since August 2011. In addition to melanoma, this mutation has been widely observed in papillary thyroid carcinoma and colorectal cancer.

An international team of investigators performed genetic and functional analyses in mice that revealed a series of stage-specific molecular alterations driving different phases of tumor evolution and uncovered mechanisms underlying this stage specificity. They reported in the July 8, 2013, issue of the journal Cancer Cell that BRAFV600E expression was sufficient for hyperplasia induction, but later stage intensified MAPK (mitogen-activated protein kinase)-signaling was required to drive both tumor progression and activation of intrinsic tumor suppression.

"Understanding the genetic makeup of different colorectal cancer subtypes will guide therapeutic decision making in the future," said senior author Dr. Allan Bradley, head of the mouse genomics team at the Wellcome Trust Sanger Institute (Hinxton, United Kingdom). "Our ability to engineer specific genetic alterations in mice allows us to study the function of cancer genes and to model specific cancer subtypes at an organismal level. Such mouse models are also invaluable for testing anticancer drugs before using them in clinical trials.”

"Our approach encapsulates the aim of cancer genomics: to discover changes to DNA responsible for cancer development and pinpoint the "Achilles heels" of cancer in order to identify new treatments," said first author Dr. Roland Rad, professor of translational oncology at the Technical University of Munich (Germany). "Our studies in mice revealed how genes cooperate to cause a specific subset of colon cancers. We identified main players, the order in which they occur during tumor progression, and the molecular processes how they turn relatively benign cell growth into threatening cancers. Such processes are targets for new treatments."

Related Links:

Wellcome Trust Sanger Institute
Technical University of Munich



Channels

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.